Cystatin C is an established biomarker for renal function, and, given the close association of chronic kidney disease and cardiovascular disease might indicate new-onset or deteriorating cardiovascular disease. However, evidence for cystatin C as a predictor of cardiovascular events is limited and controversial. We therefore aimed at investigating the role of Cystatin C as a predictor of future major adverse cardiovascular events (MACE) in a high risk-cohort of patients with coronary artery disease (CAD) . Cystatin C was measured in 1098 patients with angiographically proven CAD. Vascular events were recorded over a mean follow-up of 8.0±5.0 years. At baseline, 239 patients had T2DM and 859 did not have diabetes. During follow-up, 30.0% of our patients suffered MACE. Cystatin C proved to be a strong and independent predictor of vascular events in the total study cohort (standardized adjusted HR 1.20 [1.12-1.28], p<0.001) . When diabetes status was taken into account, cystatin C significantly predicted major cardiovascular events in non T2DM patients (HR=1.16 [1.08-1.26], p<0.001) and in patients with T2DM (HR=1.34 [1.13-1.60], p=0.001) . We conclude that cystatin C predicts major cardiovascular events in patients with coronary artery disease both among patients with type 2 diabetes and in nondiabetes individuals.
A.Mader: None. C.H.Saely: None. M.Maechler: None. B.Larcher: None. L.Sprenger: None. A.Leiherer: None. A.Muendlein: None. A.Vonbank: None. H.Drexel: None.